Zoetis Inc. (ZTS)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Ticker
ZTS
Exchange
NYSE
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Market cap
$34.02B
52-week range
$68.77 - $132.49

Valuation

Share price
$85.57 (close of Nov 18, 2026)
P/E (TTM)
14.05x
Price to book
10.30x
Price to free cash flow
15.22x
Enterprise value
$41.72B
Book value per share
$8.11

Price performance

PeriodChange
1 day+2.50%
5 days+3.63%
1 month+7.80%
3 months+15.70%
6 months+10.10%
Year to date-31.99%
1 year-27.57%
3 years-51.05%
5 years-62.06%
10 years+71.52%
All time+175.95%

Short interest

As of
Oct 30, 2026
Short % of float
4.67%
Shares short
16.72M
Days to cover
4.78
Change since prior report
-4.55%
Source
FINRA consolidated short interest

Members of Congress who disclosed ZTS trades

Gilbert Ray Cisneros · Markwayne Mullin · Jefferson Shreve · Lisa McClain · Robert Bresnahan · Byron Donalds · Julie Johnson · Rick Larsen

Super investors holding ZTS

Christopher Davis (Davis Selected Advisers) · Ruane Cunniff (Ruane, Cunniff & Goldfarb L.P.) · Ken Griffin (Citadel) · First Eagle Investment (First Eagle Investment Management, LLC) · Mairs & Power (Mairs & Power Inc) · Tweedy Browne (Tweedy Browne Company LLC) · Sarah Ketterer (Causeway Capital Management LLC) · Ray Dalio (Bridgewater Associates) · Polen Capital Mgmt (Polen Capital Management LLC) · Hillman Capital (Hillman Capital Management, Inc)

Profitability and growth

Return on equity
80.25%
Return on invested capital
23.03%*
Return on assets
17.28%
Return on capital employed
27.07%*
Gross margin
71.84%
Net margin
28.23%
EBITDA margin
42.98%
Revenue growth
2.28%
Net income growth
7.52%
Free cash flow growth
-0.65%

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash flow and balance sheet

Free cash flow yield (TTM)
6.57%
Current ratio
2.35x
Net debt to EBITDA
2.00x

Latest reported year

Period end
Dec 31, 2025
Fiscal year
2025
Revenue
$9.47B
Cost of revenue
$2.67B
Gross profit
$6.80B
EBITDA
$4.07B
Net income
$2.67B
Earnings per share
$6.03
Research and development
$698.00M
Interest expense
$222.00M
Shares outstanding
443.44M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$9.47B$6.80B$2.67B$6.03
2024-12-31$9.26B$6.54B$2.49B$5.47
2023-12-31$8.54B$5.98B$2.34B$5.08
2022-12-31$8.08B$5.63B$2.11B$4.51
2021-12-31$7.78B$5.47B$2.04B$4.29
2020-12-31$6.67B$4.62B$1.64B$3.44
2019-12-31$6.26B$4.27B$1.50B$3.14
2018-12-31$5.83B$3.91B$1.43B$2.96
2017-12-31$5.31B$3.53B$864.00M$1.76
2016-12-31$4.89B$3.22B$821.00M$1.66

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3171.84%28.23%80.25%23.03%*
2024-12-3170.62%26.86%52.12%23.63%*
2023-12-3170.03%27.43%46.96%21.96%*
2022-12-3169.63%26.16%48.01%18.67%*
2021-12-3170.38%26.20%44.83%19.93%*
2020-12-3169.18%24.54%43.41%16.71%*
2019-12-3168.18%23.96%55.39%18.42%*
2018-12-3167.19%24.52%65.35%18.87%*
2017-12-3166.55%16.28%48.38%15.39%*
2016-12-3165.92%16.80%54.77%16.51%*

* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.

Cash and debt by year

Period endCashDebt
2025-12-31$2.31B$9.04B
2024-12-31$1.99B$5.22B
2023-12-31$2.04B$6.56B
2022-12-31$3.58B$6.55B
2021-12-31$3.48B$6.59B
2020-12-31$3.60B$6.59B
2019-12-31$1.93B$5.95B
2018-12-31$1.70B$6.44B
2017-12-31$1.56B$4.95B
2016-12-31$727.00M$4.47B

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$2.28B$83.00M
2024-12-31$2.30B$74.00M
2023-12-31$1.62B$60.00M
2022-12-31$1.33B$62.00M
2021-12-31$1.74B$58.00M
2020-12-31$1.67B$59.00M
2019-12-31$1.33B$67.00M
2018-12-31$1.45B$53.00M
2017-12-31$1.12B$44.00M
2016-12-31$497.00M$37.00M

Dividend history

Most recent payment
Oct 30, 2026
Paid in the last twelve months
$2.12
Payment dateDividend per share
2026-10-30$0.53
2026-07-20$0.53
2026-04-20$0.53
2026-01-20$0.53
2025-10-31$0.50
2025-07-18$0.50
2025-04-21$0.50
2025-01-21$0.50

Investor relations

Past earnings dates

ReportedFiscal periodEPS estimate
2026-11-05Sep 2026$1.51
2026-08-06Jun 2026$1.84
2026-05-07Mar 2026$1.61
2026-02-12Dec 2025$1.40
2025-11-04Sep 2025$1.62
2025-08-05Jun 2025$1.62
2025-05-06Mar 2025$1.40
2025-02-13Dec 2024$1.37

Filings and sources

Company website
zoetis.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Viatris Inc (VTRS) · Teva Pharmaceutical Industries Ltd (TEVA) · Hims & Hers Health, Inc. (HIMS) · Haleon plc (HLN) · Novo Nordisk A S (NVO) · GSK plc (GSK) · McKesson Corp (MCK) · Organon & Co. (OGN)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades